Search Follow us

BiondVax Pharmaceuticals (BVXV)

Business description

BiondVax is developing a potentially universal influenza vaccine and the lead candidate M-001 could be positioned as a primer for seasonal or pandemic vaccines or as a standalone influenza vaccine. So far M-001 has been tested in two Phase I/II and three Phase II trials and consistently demonstrated immunogenicity to multiple virus strains.

Termination of coverage

Update | Pharmaceutical & healthcare | 16/01/2018

Since BiondVax shares are no longer traded on the Tel Aviv Stock Exchange (TASE), Edison Investment Research Ltd. has terminated coverage of the Company within the framework of the TASE analysis program.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Company news